间歇给药对肺结核治疗结局的影响:更新的系统综述与荟萃分析
该更新的系统综述与荟萃分析纳入56项随机对照试验共110个治疗臂,比较四种给药方案对初治肺结核的疗效。结果显示,全程每周三次给药和巩固期每周两次给药的复发率显著高于每日给药,且失败率和获得性耐药率更高。结论提示间歇给药方案微生物学结局劣于每日治疗。
要点
- 全程每周三次给药方案的复发率、失败率和获得性耐药率均高于每日给药。
- 巩固期每周两次给药方案的复发率和失败率高于每日给药。
- 临床应优先选择每日给药方案以改善肺结核微生物学治疗结局。
核心结论
- 全程每周三次给药和巩固期每周两次给药的微生物学治疗结局劣于每日给药方案。
研究设计与样本
- 更新的系统综述与荟萃分析,检索2008年6月至2016年3月的随机对照试验,最终纳入56项RCT共110个治疗臂。
主要发现
- 全程每周三次给药臂的合并复发比例为6.8(95%CI 3.8-9.9),巩固期每周两次给药臂为7.3(95%CI 3.5-11.1),均显著高于每日给药臂的2.5(95%CI 1.8-3.2;P<.01)。
- 荟萃回归显示,与每日给药相比,全程每周三次给药臂的复发率(2.2;95%CI 1.2-4.0)、失败率(3.7;95%CI 1.1-12.6)和获得性耐药率(10.0;95%CI 2.1-46.7)更高。
- 巩固期每周两次给药臂的失败率(3.0;95%CI 1.0-8.8)高于每日给药。
临床怎么用
- 初治肺结核应优先采用每日给药方案,避免全程每周三次或巩固期每周两次给药以降低复发、失败和获得性耐药风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Intermittent regimens offer operational advantages in tuberculosis treatment, but their efficacy has been questioned. We updated a systematic review and metaanalysis to examine the efficacy of different intermittent dosing schedules in first-line pulmonary tuberculosis therapy. METHODS: An updated search included randomized control trials (RCTs) that reported on first-line pulmonary tuberculosis therapy between June 2008 and March 2016. We pooled proportions of failure, relapse, and acquired drug resistance (ADR) for 4 dosing schedules: daily throughout, thrice weekly throughout, daily (intensive phase) then thrice weekly (continuation phase), and daily (intensive phase) then twice weekly (continuation phase). Metaregression was performed using a negative binomial regression model. RESULTS: After screening 5874 citations, 7 RCTs with 10 arms were added for a total of 56 RCTs with 110 arms. The pooled proportion of relapse was significantly higher in arms with thrice weekly therapy throughout (6.8; 95% confidence interval [CI], 3.8-9.9) and twice weekly therapy in the continuation phase (7.3; 95% CI, 3.5-11.1) when compared with daily therapy (2.5; 95% CI, 1.8-3.2; P < .01). Metaregression revealed higher rates of relapse (2.2; 95% CI, 1.2-4.0), failure (3.7; 95% CI, 1.1-12.6), and ADR (10.0; 95% CI, 2.1-46.7) in arms with thrice weekly throughout and higher rates of failure (3.0; 95% CI, 1.0-8.8) with twice weekly in the continuation phase when compared with daily therapy. CONCLUSION: Thrice weekly dosing throughout therapy, and twice weekly dosing in the continuation phase appear to have worse microbiological treatment outcomes when compared with daily therapy.
引用
- Johnston JC, Campbell JR, Menzies D, et al. Effect of Intermittency on Treatment Outcomes in Pulmonary Tuberculosis: An Updated Systematic Review and Metaanalysis. Clin Infect Dis. 2017. PMID: 28203783. doi:10.1093/cid/cix121
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。